The GLP-1 medications transforming weight loss didn’t appear overnight. They’re the result of decades of groundbreaking research that fundamentally changed how we understand appetite and obesity. But how did scientists first discover that this hormone could help people lose weight? And what does this history mean for anyone using these medications today?

Join Holly and Jim as they sit down with Dr. Arne Astrup, one of the pioneering researchers who helped uncover GLP-1’s role in appetite regulation back in the 1990s. Dr. Astrup has spent over three decades at the forefront of obesity research at the University of Copenhagen and the Novo Nordisk Foundation. In this fascinating conversation, he takes us back to when obesity was still seen as a willpower problem, reveals the serendipitous collaboration that led to discovering GLP-1’s satiety effects, and shares critical insights about using these medications safely and effectively.

Whether you’re currently using GLP-1 medications, considering them, or simply curious about the science, this episode offers essential perspective from someone who’s witnessed the entire journey from early physiology experiments to today’s real-world treatments. You’ll discover why lifestyle still matters in the era of highly effective medications, and walk away with a deeper understanding of both the promise and the limitations of these groundbreaking drugs.

Discussed on the episode:

• The surprising mindset shift in the 1990s that changed how medicine views obesity
• Why a diabetes researcher and an appetite scientist became unlikely collaborators
• The first human experiment that proved GLP-1 reduces hunger (and the lunch buffet that made it possible)
• Why GLP-1 medications are so much “cleaner” than previous weight loss drugs
• The protein malnutrition risk that doctors aren’t talking about enough.
• Why half of patients stop taking these medications within months, and what that means
• The one combination that could let you reduce or stop GLP-1s without regaining weight
• Why calling these medications “the easy way out” completely misses the point
• What a leading researcher wants to accomplish after decades of groundbreaking work

Food noise. If you’ve heard the term, you probably know exactly what it means. If you haven’t, you might be about to have a lightbulb moment. It’s that relentless mental chatter about food, not hunger, not cravings, but constant, unwanted thoughts that just won’t quit.

For years, people struggling with this phenomenon didn’t even have words for it. They thought it was a willpower problem. It wasn’t. And now, thanks to groundbreaking research, we finally have a way to understand, measure, and potentially treat this invisible burden that affects people across the weight spectrum.

Join Holly and Jim as they sit down with Dr. Emily Dhurandhar, Director of Research Special Projects at Texas Tech University Health Sciences Center, and lead author of the RAID-FN Inventory, the first validated tool to measure food noise. Discover why patients, not clinicians, coined this term, how GLP-1 medications are revealing what many have silently endured, and what the future holds for treating this pervasive issue.

Discussed on the episode:

• Why food noise is completely different from normal thoughts about food
• The surprising discovery about who experiences food noise (hint: it’s not just people with obesity)
• What turning off a kitchen fan has to do with understanding these medications
• How bodybuilders and endurance athletes might experience food noise differently
• Why your environment in the 1940s versus today changes everything
• The one word clinicians need to stop assuming about food noise
• What to do if you think you’re experiencing this, but your doctor has never heard of it

For decades, people with obesity were told the solution was simple: eat less, move more, try harder. When that didn’t work, they were blamed. But science has always told a different story: obesity is a chronic, biologically driven disease, just like diabetes or hypertension. And right now, we’re witnessing the most significant transformation in obesity medicine that has ever happened.

The new GLP-1 medications like Wegovy and Zepbound are making headlines everywhere, but with breakthrough treatments come big questions. Who should take them? How do you know which one is right for you? What happens when you stop? And with millions of people getting these medications online or from providers with little expertise, how do you ensure you’re getting safe, effective care?

Join Holly and Jim as they sit down with Dr. Louis Aronne, one of the true pioneers who shaped this revolution from the very beginning. For over 30 years, Dr. Aronne has been on the front lines, treating patients and conducting research at one of the premier obesity centers in the country. He’ll share the real story behind these medications, what he’s learned from treating 9,000 patients, and where obesity treatment is heading next.

Discussed on the episode:

• The mouse experiment from the 1980s that changed everything about how we understand weight
• Why some people feel amazing on Wegovy while others do better on Zepbound
• The creative dosing strategies that help patients who can’t tolerate standard doses
• What happens to the majority of people who stop taking GLP-1 medications
• The surprising parallel between treating obesity and treating high blood pressure
• Why registered dietitians could be the perfect providers for obesity care
• The 15 new medications coming in the next five years that will transform access
• How these medications prevent 94% of diabetes cases in people with prediabetes
• The simple eating strategy that works almost like taking medicine
• What it really means when people say taking medication is cheating